Orchard Therapeutics PLC
Dr. Mirko Essing has extensive experience in the field of Medical Affairs, holding various leadership roles in prominent pharmaceutical companies such as Orchard Therapeutics, BioMarin Europe Ltd., and Bristol-Myers Squibb. Dr. Mirko also worked as a Consultant and co-owner at PaediaCRO GmbH. With a career spanning over two decades, Dr. Essing has demonstrated their expertise in medical management and infectious diseases across different regions in Europe and the United States.
Dr. Mirko Essing completed their Graduation (Abitur) at Ratsgymnasium Bielefeld in 1989. Dr. Mirko then went on to earn their MD in medicine from the University of Münster between 1991 and 1997. Additionally, they attended Abingdon School in 1987-1988.
This person is not in any offices
Orchard Therapeutics PLC
3 followers
Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.